Gilead Sciences, Inc. (NASDAQ:GILD) is one of the Best Large Cap Value Stocks to Invest In. Analyst Courtney Breen of ...

A landmark breakthrough in HIV prevention — a scientific feat decades in the making — received final approval from the Food ...

Gilead Sciences (GILD) stock slips as the company agrees to pay $202M to settle allegations that its HIV drug promotion ...

As the Q1 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the ...

Gilead's Papao shares insights on the evolving role of public-private collaboration in healthcare, and how emerging tech is ...

CHICAGO Attorney General Kwame Raoul, as part of a bipartisan coalition of 49 attorneys general, announced a $202 million multistate settlement agreement ...

Massachusetts AG Campbell secures $1.6 million for the state's Medicaid in a settlement with Gilead over illegal kickbacks ...

Gilead Sciences will pay more than $200 million after admitting to a multi-year illegal kickback scheme that pushed its HIV drugs through lavish perks for prescribers. New York Attorney General ...

Previous treatment for depression, high BMI and inflammation levels, and early signs of functional impairment may be risk factors for physical function decline in HIV.

"Government health care dollars are precious and must be used without favor in order to achieve the highest possible health ...

Despite the recent approval of lenacapavir as a twice yearly PrEP, there is still a need for choice in HIV prevention, argue ...

SA has accepted an offer of just over R520-million from the Global Fund to Fight Aids, TB and Malaria to buy the twice-a-year ...